The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Determining the glioma CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide methylation data in the biomarker cohort of the NOA-04 trial.
Benedikt Wiestler
No relevant relationships to disclose
David Capper
No relevant relationships to disclose
Volker Hovestadt
No relevant relationships to disclose
Martin Sill
No relevant relationships to disclose
David Jones
No relevant relationships to disclose
Christian Hartmann
No relevant relationships to disclose
Joerg Felsberg
No relevant relationships to disclose
Michael Platten
No relevant relationships to disclose
Kathy Keyvani
No relevant relationships to disclose
Stefan Pfister
No relevant relationships to disclose
Otmar Wiestler
No relevant relationships to disclose
Richard Meyermann
No relevant relationships to disclose
Guido Reifenberger
No relevant relationships to disclose
Torsten Pietsch
No relevant relationships to disclose
Andreas von Deimling
No relevant relationships to disclose
Michael Weller
Consultant or Advisory Role - Merck Serono; MSD; Roche
Research Funding - Merck Serono; Roche
Wolfgang Wick
Consultant or Advisory Role - Apogenix (U); MSD; Roche
Honoraria - Roche
Research Funding - Apogenix; Boehringer Ingelheim; Roche